Navigation Links
BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
Date:2/23/2009

MOUNTAIN VIEW, California, February 23 /PRNewswire/ -- BN ImmunoTherapeutics, Inc. today provided updated data from its clinical studies with its breast cancer vaccine, MVA-BN(R)-HER2, in development as therapy of metastatic breast cancer patients whose tumours over-express HER2. The study met its primary endpoint with regards to safety and by showing an immune response. Evidence of vaccine-induced anti-HER2 immune response was detected in approximately 70% of evaluated patients.

Clinically, the vaccine was well tolerated with no treatment-related severe adverse events. Currently, the disease has not progressed in 15 out of the 30 patients after a 6 month period. Also, in the group where vaccine was combined with chemotherapy, one complete response and one partial response were observed. These results confirm the positive interim data reported in 2008 and show that MVA-BN(R)-based, HER2 directed vaccination is a biologically active treatment for patients with HER2 positive breast cancer; however the overall immune response was moderate.

Additionally BN ImmunoTherapeutics has completed preclinical studies with an improved version of the MVA-BN(R)-HER2 vaccine. In those studies, the new vaccine induced up to 20-fold higher T-cell immune response as compared to the original version. Furthermore, it proved to be efficacious in additional tumour immunotherapy models in HER2 transgenic mice. The immunological situation regarding HER2 in those mice strongly resembles the situation in humans.

Based on those encouraging data from both clinical and preclinical studies BN ImmunoTherapeutics decided to advance the clinical development of MVA-BN(R)-HER2 in further clinical studies with the new and improved vaccine. Specifically, a new, single-site Phase I/II study in the US will be initiated by 2009 and evaluate 24 patients in both metastatic breast cancer as well as in an adjuvant therapy of breast can
'/>"/>

SOURCE BN ImmunoTherapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
2. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
7. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
8. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
9. BioCryst Updates Peramivir Clinical Development Plan
10. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
11. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Apnea Sciences ( www.apneasciences.com ) ... Aliso Viejo , California.  Jimmy ... tremendous growth and worldwide expansion, a new facility with ... the anti snore cure have exceeded our expectations and ... are now in 23 countries and will be increasing ...
(Date:12/22/2014)...   TRU-D SmartUVC LLC, producers of the ... today that the General Services Administration has awarded the ... This newly formed agreement will allow TRU-D ... purchasers, including Department of Veteran Affairs and Department of ... purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)... 2014  ConvaTec, a privately-held medical products and technologies ... Interim Chief Executive Officer of the company, effective December ... Berger .  "The Board of Directors of ConvaTec thanks ... the past three years," said Magnus Lundberg , ... confident that the company is well positioned for the ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... Dimes Publishes Findings in Nature Medicine, WHITE PLAINS, ... study of pre-eclampsia, a serious and potentially deadly,disorder that ... in mice that may have important implications for diagnosis,and ... Rodney E. Kellems, Ph.D., Department of,Biochemistry and Molecular Biology; ...
... NEW YORK, July 28 Polyphenon Pharma, an ... and,Drug Administration (FDA) has granted Orphan Drug Designation ... of chronic lymphocytic,leukemia (CLL). A Phase II study ... Minnesota where researchers are studying the effects of ...
Cached Medicine Technology:New Research on Pre-Eclampsia in Mice May Have Important Implications for Humans 2Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL 2
(Date:12/21/2014)... By Dennis Thompson ... -- Former tobacco smokers find e-cigarettes less addictive than traditional ... e-cigarettes as often as they did regular cigarettes, thousands of ... to feel impulsive and irritable over their need to smoke, ... clear. The score was significantly less for e-cig use than ...
(Date:12/21/2014)... 2014 The number of Mirena lawsuits ... litigation underway in New Jersey, Bernstein Liebhard LLP reports. ... claims involving the birth control IUD have now been ... filed by women who allege spontaneous migration of the ... perforations and other complications they were inadequately warned about ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Serious Buyer, ... for Vintage 1967 Jm Morrison and the Doors International Ballroom ... This would also be the only time that Morrison's ... was on Nov. 25, 1967. According to Hawley, “This ... They did play the Alexandria Roller Rink earlier that ...
(Date:12/21/2014)... CA (PRWEB) December 21, 2014 Over ... resolved performance issues in hundreds of emergency departments across ... satisfaction. Its findings have been translated into an innovative ... leaders to correct deficiencies and enhance the patient experience. ... outsourced emergency physician staffing and management services for hospitals, ...
(Date:12/21/2014)... December 21, 2014 Theme ... a new intro plugin for Final Cut Pro X ... videos, logos, and more with absolute ease.” Said Christiana ... users the tools needed to easily animate their media ... Cut Pro X users to animate pictures, videos, logos, ...
Breaking Medicine News(10 mins):Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2
... Lvov, a chemistry professor in Louisiana Techs Institute for ... the Year, beating candidates from Princeton University and companies ... in the journals January 2008 issue. , Lvov received ... cancer drugs. His research pioneers drug reformulation through polyelectrolyte ...
... YORK, Dec. 5 At a briefing ... vice president -- DuPont,Performance Materials, discussed the ... $6 billion in annual sales, the DuPont,Performance ... value-added applications development for the global,packaging, transportation, ...
... event of its kind in the country, provides ... healing and other resources, ... District, is hosting the fourth,Breaking The Silence 2007: A Summit on ... - 8 p.m. and Saturday,December 8, 8 a.m. - 3 p.m. ...
... Protalix,BioTherapeutics, Inc. (Amex: PLX ), announced today ... Jane H. Hsiao, Ph.D., have resigned from,the Company,s ... reasons. Dr. Hsiao was a member of the ... Protalix BioTherapeutics, Inc., Protalix is a biopharmaceutical ...
... As companies transform their,call centers into service-to-sales operations, ... while maintaining a customer service,function. Because they play ... is one of the key factors behind a ... leaders recommend reducing spans of control by as,much ...
... Resources to Coordinate Care, NEWTON, Mass., Dec. ... as a major cause of stress and functional ... in America are in a,silent crisis; overwhelmed by ... or elderly family member. These families face a,multitude ...
Cached Medicine News:Health News:Louisiana Tech professor is Small Times' Innovator of the Year 2Health News:DuPont Group Vice President Briefs Investors on Performance Materials Segment 2Health News:Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes' Behavioral Mental Health Summit 2Health News:Protalix BioTherapeutics Announces Resignation of Board Members 2Health News:Managing the Service-to-Sales Cultural Transformation - Complimentary Excerpt Available from Best Practices 2Health News:Family Caregivers in Crisis Have New Hope 2
Fine 3.0 mm platformed angled 60 degrees 10 mm from angle to tip. Serrated handle with dull finish....
Tennant straight tying forceps, 6.0 mm tying platforms, with pin, extra delicate smooth jaws....
Sinskey tying forceps, straight, fine, 7 mm tying platforms....
O'Gawa-Castroviejo tying forceps, straight shafts, 6 mm tying platforms, wide handle....
Medicine Products: